Three Trials Examine Dupilumab in Moderate-to-Severe Asthma

(MedPage Today) -- Three abstracts evaluating dupilumab (Dupixent) for moderate-to-severe asthma were presented at the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting: VESTIGE, a phase IV trial which evaluated...
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news